| Autor: |
Bolleddula J; Department of Drug Metabolism and Pharmacokinetics , Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA, USA., DeMent K, Driscoll JP, Worboys P, Brassil PJ, Bourdet DL |
| Jazyk: |
angličtina |
| Zdroj: |
Drug metabolism reviews [Drug Metab Rev] 2014 Aug; Vol. 46 (3), pp. 379-419. Date of Electronic Publication: 2014 Jun 09. |
| DOI: |
10.3109/03602532.2014.924962 |
| Abstrakt: |
Aliphatic nitrogen heterocycles such as piperazine, piperidine, pyrrolidine, morpholine, aziridine, azetidine, and azepane are well known building blocks in drug design and important core structures in approved drug therapies. These core units have been targets for metabolic attack by P450s and other drug metabolizing enzymes such as aldehyde oxidase and monoamine oxidase (MAOs). The electron rich nitrogen and/or α-carbons are often major sites of metabolism of alicyclic amines. The most common biotransformations include N-oxidation, N-conjugation, oxidative N-dealkylation, ring oxidation, and ring opening. In some instances, the metabolic pathways generate electrophilic reactive intermediates and cause bioactivation. However, potential bioactivation related adverse events can be attenuated by structural modifications. Hence it is important to understand the biotransformation pathways to design stable drug candidates that are devoid of metabolic liabilities early in the discovery stage. The current review provides a comprehensive summary of biotransformation and bioactivation pathways of aliphatic nitrogen containing heterocycles and strategies to mitigate metabolic liabilities. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
